Actorius featured on BBC News Click Kannada with expert and patient insights. Press Release 22 March 2019 Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. In this special feature on BBC News Click Kannada, Actorius Innovations and Research highlights its advancements in cancer diagnostics and liquid biopsy technology. Dr. Jayant Khandare shares insights into the science and vision behind the innovation, while renowned experts Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi provide clinical perspectives on its impact. The segment also includes powerful patient testimonials, underscoring the real-world significance of early and minimally invasive cancer detection. Watch the video Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius at ESMO 2025 Events 17 October 2025 ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Some Glimpses from ESMO Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius and ACTREC Partner to Advance Clinical Cancer Research. Press Release 5 February 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Big step forward for Actorius Innovations and Research 🙌 Actorius recently signed an MOU with Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) to collaborate on clinical studies and research spanning - practical utility of Circulating Tumor Cells and their capture and depletion from patient’s blood as possible aid to adjunct therapeutics. Slowing down or blocking metastasis cascade in early stage patients. Extremely bold and breakthrough innovation hypothesis. This partnership is about taking science closer to patients—generating meaningful real-world evidence, strengthening translational research, and asking the right clinical questions where it truly matters. The MOU was signed by Dr. Pankaj Chaturvedi , Director, ACTREC, and Dr. Jayant Khandare , Co-Founder & CSO, Actorius Innovations and Research. Excited about what lies ahead and the impact this collaboration can create together. Aravindan Vasudevan Rick Kamble Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

TSG mutations predict early relapse in mEGFR lung adenocarcinoma. Publications 14 March 2025 Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Background: Lung adenocarcinoma frequently presents with EGFR mutations, often progressing on EGFR tyrosine kinase inhibitors (TKls) despite an initial response. Progression is frequently driven by additional genetic changes, including mutations in tumor suppressor genes (TSGs). Understanding the role of these concurrent TSG mutations can help elucidate resistance mechanisms and guide the development of more effective treatment approaches. Materials and methods: We examined survival outcomes in 483 EGFR-mutant (mEGFR) patients from the GENIE BPC non-small-cell lung cancer (SCLC) dataset. To understand the mutational landscape and clonal dynamics, whole exome sequencing (WES) was carried out on 48 tumor samples from 16 mEGFR patients at both baseline and post-relapse. A comprehensive gene panel was applied to 200 liquid biopsy samples obtained longitudinally from 25 patients to track clonal evolution. Results: mEGFR patients with co-occurring TSG mutations exhibited significantly worse outcomes. In the GENIE dataset, overall survival (OS) was shorter [51.11 versus 99.3 months; hazard ratio (HR) 1.8, confidence interval (CI) 1.22-2.75, P = 0.003] and progression-free survival (PFS) was reduced (9.83 versus 11.48 months; HR 1.4, CI 1.03-1.91, P=0.026). WES analysis revealed 17 TSG mutations that were retained and showed clonal enrichment, particularly in early relapse (progression within 10 months of TKI initiation) or intermediate-stage relapse (relapse occurred between 10 and 20 months), indicated by increased variant allele frequency and their presence was strongly linked to early relapse. Longitudinal clonal studies further confirmed that TSG mutations co-occurring with mEGFR were often truncal, predominantly in early relapsers. Survival analysis using this subset of 17 TSGs showed significantly shorter OS (55.26 versus 99.3 months; HR 1.7, CI 1.12-2.65, P = 0.011) and PFS (9.67 versus 13.12 months; HR 1.5, CI 1.08-2.10, P = 0.013). Conclusions: A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Key words: lung adenocarcinoma, tyrosine kinase inhibitor, whole exome sequencing, comprehensive gene panel, tumor suppressor genes View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | ANI News Press Release 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Chemo-specific designs for the enumeration of CTCs: advances in liquid biopsy Publications 18 December 2020 Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Advanced materials and chemo-specific designs at the nano- and micrometer scale have ensured revolutionary progress in next-generation clinically relevant technologies. For example, isolating a rare population of cells, such as circulating tumor cells (CTCs) from blood among billions of other blood cells, is one of the most complex scientific challenges in cancer diagnostics. Achieving this level of exceptional specificity for extracellular biomarker interactions requires chemical tunability through the use of advanced materials and multistep reactions in both solution and insoluble states. This review delineates the chemo-specific substrates, chemical methods, and structure–activity relationships (SARs) of chemical platforms used for the isolation and enumeration of CTCs, thereby advancing the relevance of liquid biopsy in cancer diagnostics and disease management. We highlight the synthesis of cell-specific, tumor biomarker-based chemo-specific substrates utilizing functionalized linkers through chemistry-based conjugation strategies. The capacity of these nano- and micro-scale substrates to enhance interaction specificity and efficiency with targeted tumor cells is discussed in detail. Furthermore, this review emphasizes the importance of CTC capture and downstream processes involving genotypic and phenotypic CTC analysis in real time. These approaches enable early detection of metastasis progression, evaluation of chemotherapy treatment response, and monitoring of progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) in cancer patients. Royal Society of chemistry. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 detection reveals residual disease despite clear radiological scans. Publications 4 June 2024 ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Background Despite no evidence of disease by radiological imaging, up to 30% of breast cancer cases are known to relapse after treatment with curative intent. The presence of circulating tumor cells (CTCs) in stage I–II cancer patients signals the activation of extravasation and invasion processes leading to micro-metastasis and may result in poor outcomes. CTCs in blood circulation at any stage of cancer indicate detectable minimal cellular disease (MCD). Thus, the longitudinal investigation of patients with such biomarkers remains highly important for predicting recurrence, therapy escalation, and dose modifications. The expression of programmed death-ligand 1 (PD-L1) on CTCs is a dynamic biomarker, and these cells may escape elimination by the immune system, indicating progression toward a metastatic phenotype. Methods Retrospectively, a cohort of 20 cancer patients (including lung, colorectal, breast, stomach, etc.) who had recently undergone treatment were investigated for the presence of CTCs using the CDSCO-approved OncoDiscover platform. The platform contains multi-component systems conjugated with anti-EpCAM antibodies on magnetic nanoparticles. All patients clinically represented stable disease based on previous radiological findings. CTC enumeration was performed using CD45-, EpCAM+, and CK18+ markers, along with the evaluation of PD-L1 overexpression in 1.5 ml of peripheral blood using automated motorized Zeiss fluorescence microscopy. Results Despite no radiological evidence of disease and clinically stable status, 75% (n = 15) of the selected patients showed at least one CTC. Among them, 55% (n = 11) had one CTC, 5% (n = 1) had two CTCs, and 15% (n = 3) had three CTCs. In addition, 50% (n = 10) of patients demonstrated PD-L1 expression on CTCs, while one patient exhibited a CTC cluster. Conclusions Patients showed circulating residual disease (CRD) despite clinically stable disease, indicating possible progression from localized to secondary disease. Longitudinal monitoring of CTCs with PD-L1 expression may reveal real-time residual disease, progression, regression, and actual response to treatment. CRD monitoring can improve curative outcomes by potentially enhancing progression-free survival (PFS) and overall survival (OS) in solid cancers. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs track residual disease and therapy response in breast cancer patients. Publications 6 June 2023 ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Background Breast malignancies are a leading cause of cancer-related mortalities and show an ascending incidence rate. Despite advancements in our understanding of the disease, its clinical outcome is often dismal. This largely remains owing to the characteristic wide window of relapse, spanning months to decades after primary treatment. Therefore, continuous monitoring of the disease is an offered choice to detect metastatic progression and recurrence. Circulating tumor cells (CTCs) have emerged as a powerful prognostic tool to predict the disease outcome in many epithelial cancers. CTCs are a real-time surrogate biomarker accounting for minimal residual disease (MRD) which is often missed in CT PET scanning. This leads to a progression of metastasis when the patient is often considered as 'clinically disease free'. Here, we analyzed the presence of CTCs in treatment-naive and chemo-recipient breast cancer patients. Methods In this retrospective study on 417 breast cancer patients, CTCs were isolated from 1.5 ml of blood using the Drug Controller General of India (DCGI) approved OncoDiscover CTC test. This platform contains affinity-based magnetic nanoparticles to mediate EpCAM-based CTC isolation. CTCs were detected as CK18+, DAPI+ and CD45- cells based on an automated digital imaging platform. Results 42.6% (n=178) of patients were clinically at a progressive stage (stage II and III) and treatment-naive. On the other hand, 47.4% of patients received treatment including surgery and chemotherapy. CTCs were not observed in 5.6% (n=10) of the treatment-naive population, while 32% (n=75) of patients who received therapy did not show CTCs. The mean CTC number in treatment-naive patients was 15, while the mean CTC count in patients receiving therapy was drastically reduced to 2. This implied that therapy effectively countered the tumor progression and reduced the shedding of tumor cells in circulation. The distribution of CTC in treatment-naive patients exhibited a bimodal trend centered at values of 10 and 50, suggesting two distinct populations of patients with respect to CTC count. CTC count did not show any correlation with the age in both population groups. Surprisingly, CTC count in younger patients (20-50 years) was 50% higher compared to the older population (50-75 years). Conclusions The presence of CTCs in treatment-naive, progressive breast cancer patients indicated biologically aggravated disease. Although therapeutic intervention drastically reduced the CTC burden, their presence in a large population was suggestive of an MRD and the likelihood of recurrence after discontinuation of therapy. A distinct pattern of CTC occurrences in Tx naive and Tx recipient patients suggested that CTCs can be an important clinical indicator to monitor the therapy response, progression, and residual disease. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dual ctDNA and CTC biomarkers improve detection of cancer progression. Publications 3 June 2024 ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Background Genomic mutations identified from circulating tumor DNA (ctDNA) have been shown to correlate positively with clinical disease status. EGFR and intracellular cell progression and proliferation pathways involving BRCA1/2 and TP53 genes drive high ctDNA load in progressive cancer patients. Circulating tumor cells (CTCs) indicate cellular residual disease (CRD). Together, ctDNA and CTCs as dual biomarkers offer predictive insights into tumor progression and metastasis, which may be valuable for early detection and treatment modifications. Methods In a retrospective study, 96 cancer patients (including lung, colorectal, breast, stomach, and other cancers) who had recently undergone treatment were investigated for the presence of CTCs and genomic mutations from ctDNA using the OncoMonitor test. Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 platform. The test detected genomic alterations including single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions) using a 96-gene panel. CTCs were isolated using the OncoDiscover platform and identified as CK18+, PD-L1+, CD45- cells in 1.5 ml of blood. Results Among the 96 pan-cancer patients, 15.6% (n = 15) were identified with localized progressive disease without metastasis based on radiological findings, of which 60% (n = 9) showed at least one genomic alteration detected from ctDNA. Additionally, 12.5% (n = 12) patients were identified with metastatic disease from radiological findings, of which 58.3% (n = 7) showed the presence of at least one CTC. Among these, 33.3% (n = 4) patients had two CTCs, while five patients had no detectable CTCs. Furthermore, metastatic patients showed ctDNA load in 66.6% (n = 8) of cases with at least one genomic finding. In the metastatic disease cohort, CTC enumeration showed a concordance of 58.3% (n = 7) with metastatic radiological findings, while genomic findings from ctDNA showed a concordance of 66.6% (n = 8) with metastatic radiological findings. Among 23.9% (n = 23) patients identified radiologically with stable or treatment-responsive disease, 73.9% (n = 17) had no detectable genomic mutations from ctDNA, and 26.0% (n = 6) were CTC-negative, consistent with radiological findings. However, 26.0% (n = 6) patients had at least one genomic finding, contributing to discordance with radiological findings. Overall, genomic findings from the dual biomarkers showed concordance with radiological findings in 26.6% (n = 4) patients with progressive disease, 41.6% (n = 5) patients with metastatic disease, and 17.3% (n = 4) patients with stable or treatment-responsive disease. Conclusions Patients with progressive and metastatic disease identified through radiological findings showed concordance with dual ctDNA and CTC biomarkers. The concordance of ctDNA in progressive disease and CTC detection in metastatic disease highlights the individual significance of these biomarkers and supports their combined use for monitoring disease status and guiding treatment decisions. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

EMF triplet therapy and CTC monitoring improve HNSCC outcomes and predict response. Publications 7 June 2022 ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. Background Head and neck cancer is a huge burden in South East Asia with frequent relapse after curative therapy, while the rest present in advanced unresectable stages. Financial constraints for targeted and immunotherapy make it inaccessible for the bulk of the population. Thus, a low-cost but efficacious regimen is highly implicated. We assessed if the readily available triplet therapy of EMF is superior in terms of extending life and maintaining quality of life, along with the evaluation of CTCs as a predictive biomarker in such patients. Methods This was a single-arm, phase II, investigator-initiated interventional study, wherein 35 patients were enrolled. Platinum-resistant/refractory patients of HNSCC were treated with a combination of erlotinib 150 mg daily, methotrexate 40 mg/m2, and 5-fluorouracil 500 mg/m2 (d1, d8) q28 days till progression or unacceptable toxicities. The primary endpoint was the overall response rate (ORR) at 3 months; additional endpoints were disease control rate (DCR) at 3 months, overall survival (OS), progression-free survival (PFS), safety, and patient-reported quality of life (QOL). The role of CTCs in gauging the responders and non-responders was monitored using anti-Epithelial Cell Adhesion Molecule antibody-based enrichment on the OncoDiscover Drug Controller General of India (DCGI) approved platform. Results The ORR and DCR at 3 months were 45.7% and 68.5%, respectively. The median PFS was 5 months (95% CI: 3.9-6 months) and median OS was 9 months (95% CI: 7.4-10.5 months). The 3- and 6-month PFS rates were 86 ± 6% and 45 ± 9%, respectively, while OS rates at 3 and 6 months were 91 ± 5% and 68 ± 8%, respectively. Rash, mucositis, and fatigue were common adverse events occurring in 23 (65%), 14 (40%), and 9 (25.7%) patients respectively. The grade 3 events seen were rash in 5 (14.2%) and diarrhea in 2 (5.7%). Clinically significant improvement was seen in domains of role functioning, social functioning, fatigue, pain and global health status, swallowing, dryness of mouth, and feeling ill. The mean CTC count at baseline was 0.90 ± 1.1 / 1.5 ml of blood. Responders showed a decline in levels from 1.19 ± 0.25 to 0.33 ± 0.48, while non-responders had an increasing trend: 0.29 ± 0.48 to 1 ± 0.10 at 3 months (p = 0.010); with concordance rates with response being 52.9%. Additionally, CTC clearance at 3 months had a numerically better PFS of ~6 months (95% CI: 4.72-7.72) and OS of 10 months (95% CI: 2.3-5.65) vs 4 months (95% CI: 2.3-5.65), p = 0.258, and 8 months (95% CI: 4.3-11.6), p = 0.203 in those with persistence of CTCs. Conclusions The triplet regimen of EMF is a feasible, safe therapeutic option with favorable response rates and improved QOL in patients with platinum-resistant/refractory HNSCC. CTCs have a promising futuristic role as a predictive biomarker and can be extrapolated in the clinical upfront setting too. Clinical Trial Information CTRI/2020/02/023378. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Publications 27 April 2022 Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Wearable, point-of-care diagnostics, and biosensors are on the verge of bringing transformative changes in detection, management, and treatment of cancer. Bioinspired materials with new forms and functions have frequently been used, in both translational and commercial spaces, to fabricate such diagnostic platforms. Engineered from organic or inorganic molecules, bioinspired systems are naturally equipped with biorecognition and stimuli-sensitive properties. Mechanisms of action of bioinspired materials are deeply connected with thermodynamically or kinetically controlled self-assembly at the molecular and supramolecular levels. Thus, integration ofbioinspired materials into wearable devices, either as triggers or sensors, brings about unique device properties usable for detection, capture, or rapid readout for an analyte of interest. In this review, we present the basic principles and mechanisms of action of diagnostic devices engineered from bioinspired materials, describe current advances, and discuss future trends of the field, particularly in the context of cancer. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover: affordable, rapid CTC platform for HNC patients in developing nations. Publications 4 June 2019 ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Background Liquid biopsy technologies are often unaffordable and unavailable in developing countries, despite these regions having the highest cancer burden and mortality rates. Current circulating tumor cell (CTC) technologies face significant clinical concerns, including non-specificity, low efficiency, high blood volume requirements, long turnaround times, and exorbitant costs (~$900–$1,400). We report an extremely low-cost, innovative nanosystem for the rapid enumeration of CTCs with higher specificity and efficiency. Methods We designed a nanosystem mediated by the conjugation of anti-EpCAM through a multi-reactive glutathione spacer, a carbon allotrope, and an amine-terminated dendrimer. The platform was evaluated for enhanced aqueous dispersibility and increased interaction with CTCs for rapid isolation and enumeration in 100 head and neck cancer (HNC) patients. These patients had various primary tumor sub-sites, including the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, salivary gland, and thyroid. The captured cells were immunostained, and the optimal fluorescence acquisition intensity was validated by accounting for CTCs with CK18 protein expression. Our method achieved the complete elimination of false-positive normal cell (NC) counts. The analysis was performed using only 1.5 ml of collected blood samples. Results The CTC distribution in the cohort study ranged from 1 to 85 cells per 1.5 ml of blood. In more than 80% of patients' CTCs, the quantitative estimation of anti-CK18 protein overexpression indicated an intensity approximately 10-fold higher than that of normal cells. Compared to treatment-naive, recurrent, and disease-free patients, the spread of CTC numbers across the clinical range appeared to be tight (close to the mean value). The CTC enumeration sensitivity linearity was ~99.2%, and the complete enumeration process time was under 3 hours per 1.5 ml of blood. Consequently, an efficient, rapid, and affordable CTC platform was designed and clinically validated. Conclusions The "OncoDiscover" liquid biopsy technology for CTC enumeration is poised to revolutionize the field due to its high sensitivity and affordability (~$120). It addresses a major unmet medical need in the developing world. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe